Cargando…

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction

BACKGROUNDS: Fimasartan is the most recently developed, potent, and long-acting angiotensin II receptor blocker (ARB). However, data are limited regarding treatment effects of fimasartan in patients with heart failure. METHODS: Between 2010 and 2016, patients who underwent coronary revascularization...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jihoon, Kang, Danbee, Kim, Sung Eun, Park, Hyejeong, Park, Taek Kyu, Lee, Joo Myung, Yang, Jeong Hoon, Song, Young Bin, Choi, Jin-Ho, Choi, Seung-Hyuk, Gwon, Hyeon-Cheol, Guallar, Eliseo, Cho, Juhee, Hahn, Joo-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293657/ https://www.ncbi.nlm.nih.gov/pubmed/37365730 http://dx.doi.org/10.3346/jkms.2023.38.e202

Ejemplares similares

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
por: Kim, Song-Yi, et al.
Publicado: (2016)

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
por: Kim, Tae Hwan, et al.
Publicado: (2016)

Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study
por: Yang, Jeong Hoon, et al.
Publicado: (2014)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

Fimasartan for Remodeling after Myocardial Infarction
por: Lim, Byung-Kwan, et al.
Publicado: (2019)

Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report
por: Park, Dae Hwa, et al.
Publicado: (2017)

Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2
por: Kim, Soojeong, et al.
Publicado: (2015)

Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study
por: Oh, Gyu Chul, et al.
Publicado: (2020)

Long-Term Outcomes in Patients Undergoing Percutaneous Coronary Intervention with or without Preprocedural Exercise Stress Test
por: Kim, Jihoon, et al.
Publicado: (2019)

Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
por: Kim, Inho, et al.
Publicado: (2019)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

Comparison of Exercise Performance and Clinical Outcome Between Functional Complete and Incomplete Revascularization
por: Kim, Jihoon, et al.
Publicado: (2020)

Prognostic Factors of Renal Outcomes after Heart Transplantation: A Nationwide Retrospective Study
por: Jeon, Junseok, et al.
Publicado: (2021)

Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis
por: Cho, Jang-Hee, et al.
Publicado: (2018)

Use of intravascular ultrasound and long-term cardiac death or myocardial infarction in patients receiving current generation drug-eluting stents
por: Lee, Sang Yoon, et al.
Publicado: (2022)

Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service
por: Park, So Jin, et al.
Publicado: (2019)

Differential Clinical Outcomes Between Angiographic Complete Versus Incomplete Coronary Revascularization, According to the Presence of Chronic Kidney Disease in the Drug‐Eluting Stent Era
por: Kim, Jihoon, et al.
Publicado: (2018)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
por: Choi, Jin Sun, et al.
Publicado: (2023)

Effect of sarpogrelate and high‐dose statin on the reduction of coronary spasm in vasospastic angina: A two by two factorial, pilot randomized study
por: Kim, So Ree, et al.
Publicado: (2019)

Fimasartan reduces neointimal formation and inflammation after carotid arterial injury in apolipoprotein E knockout mice
por: Kim, Jong-Ho, et al.
Publicado: (2019)

Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2018)

Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction
por: Lee, Seung Hun, et al.
Publicado: (2023)

Proton Pump Inhibitor Use Increases Pyogenic Liver Abscess Risk: A Nationwide Cohort Study
por: Oh, Joo Hyun, et al.
Publicado: (2021)

Effects of Fimasartan/Amlodipine Fixed-Dose Combination on Left Ventricular Systolic Function and Infarct Size in Rat Myocardial Infarction Model
por: Kim, Han Byul, et al.
Publicado: (2019)

Health disparities of critically ill children according to poverty: the Korean population-based retrospective cohort study
por: Park, Esther, et al.
Publicado: (2021)

Clinical impact of intra-aortic balloon pump during extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock
por: Park, Taek Kyu, et al.
Publicado: (2014)

Clinical Implications of Early Exercise Treadmill Testing after Percutaneous Coronary Intervention in the Drug-eluting Stent Era
por: Cho, Sung Woo, et al.
Publicado: (2020)

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

Impact of Renal Replacement Therapy on Mortality and Renal Outcomes in Critically Ill Patients with Acute Kidney Injury: A Population-Based Cohort Study in Korea between 2008 and 2015
por: Hwang, Subin, et al.
Publicado: (2022)

High‐Intensity Versus Non‐High‐Intensity Statins in Patients Achieving Low‐Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention
por: Kim, Juwon, et al.
Publicado: (2018)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Prognosis and Medical Cost of Measuring Fractional Flow Reserve in Percutaneous Coronary Intervention
por: Hong, David, et al.
Publicado: (2022)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Late Survival Benefit of Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Coronary Chronic Total Occlusion: A 10‐Year Follow‐Up Study
por: Park, Taek Kyu, et al.
Publicado: (2021)

Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
por: Lee, Jae-Geun, et al.
Publicado: (2023)

The effect of bed-to-nurse ratio on hospital mortality of critically ill children on mechanical ventilation: a nationwide population-based study
por: Jung, Minyoung, et al.
Publicado: (2020)

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
por: Hong, Keun-Sik, et al.
Publicado: (2021)

Changes in acute kidney injury epidemiology in critically ill patients: a population-based cohort study in Korea
por: Hwang, Subin, et al.
Publicado: (2019)

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
por: Shin, Eun-Seok, et al.
Publicado: (2023)

Prognostic implications of post-percutaneous coronary intervention neutrophil-to-lymphocyte ratio on infarct size and clinical outcomes in patients with acute myocardial infarction
por: Hong, David, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dc1t2276t9p92h54rid55rqefs